Optimal treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) requires nuanced, individualized treatment strategies given the diverse disease manifestations and severity. Achieving complete resection is rare, leaving patients reliant on chronic, supportive management. Mitogen-activate protein kinase (MEK) inhibitors provide a novel, targeted treatment option for reducing tumor size and patient morbidity. In this second of two videos, join two experts in a discussion covering the role and limitations of supportive care, safety and efficacy of current and emerging MEK inhibitors, and clinical implications of the latest data regarding these therapies for NF1-associated PN. You will also gain immediate access to downloadable evidence to reference in your daily practice.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/advancements-nf-1-pn-management-supportive-care-cutting-edge-therapies
- Start Date: 2024-09-11 05:00:00
- End Date: 2024-09-11 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Springworks Therapeutics - Amount: 24875.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all